What's Happening?
SQ Innovation has announced the results of the SUBCUT HF II trial, which evaluated the efficacy and safety of Lasix ONYU, a subcutaneous formulation of furosemide, for treating edema in heart failure patients at home. The trial involved 172 patients,
with 92 receiving at-home treatment and 80 receiving standard in-hospital intravenous diuretics. The study found that patients treated at home spent an average of four fewer days in the hospital compared to those receiving traditional care. The trial met its primary endpoint of reducing hospital days, demonstrating that at-home treatment is both effective and safe. The results were presented at the Heart Failure 2026 congress in Barcelona.
Why It's Important?
The findings from the SUBCUT HF II trial could significantly impact the management of heart failure, a condition that leads to over 1.2 million hospital admissions annually in the U.S. By enabling at-home treatment, the healthcare system could see reduced hospital overcrowding and lower costs associated with inpatient care. This approach also offers patients greater comfort and convenience, potentially improving their quality of life. The success of Lasix ONYU in this trial suggests a shift towards more home-based care solutions, which could transform treatment paradigms for chronic conditions.
What's Next?
Following the positive trial results, SQ Innovation may seek to expand the use of Lasix ONYU for at-home treatment of heart failure-related edema. Regulatory bodies and healthcare providers will likely evaluate the broader implementation of this treatment method. Further studies could be conducted to confirm long-term benefits and safety, potentially leading to wider adoption in clinical practice. The healthcare industry may also explore similar at-home treatment options for other conditions, leveraging the success of this trial.
